PriceTargets.com logo

Travere Therapeutics - TVTX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $32.91
  • Forecasted Upside: 46.33%
  • Number of Analysts: 10
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$22.49 As of 03/31/2023 01:00 AM ET
▲ +0.4 (1.81%)

This chart shows the closing price for TVTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Travere Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TVTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TVTX

Analyst Price Target is $32.91
▲ +46.33% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Travere Therapeutics in the last 3 months. The average price target is $32.91, with a high forecast of $42.00 and a low forecast of $17.00. The average price target represents a 46.33% upside from the last price of $22.49.

This chart shows the closing price for TVTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 10 contributing investment analysts is to buy stock in Travere Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/8/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/6/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/6/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/5/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
10/3/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
1/1/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
3/2/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
4/1/2023

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/13/2023Piper SandlerLower Target$44.00 ➝ $41.00Low
2/28/2023GuggenheimInitiated CoverageBuy$37.00Low
2/28/2023Canaccord Genuity GroupLower TargetBuy$44.00 ➝ $42.00Low
2/22/2023Canaccord Genuity GroupBoost TargetBuy$40.00 ➝ $44.00Low
2/21/2023Evercore ISIBoost Target$30.00 ➝ $36.00Low
2/21/2023Piper SandlerBoost TargetOverweight$42.00 ➝ $46.00Low
2/21/2023HC WainwrightBoost TargetBuy$36.00 ➝ $40.00Low
2/21/2023BarclaysLower TargetOverweight$37.00 ➝ $31.00Low
2/21/2023WedbushUpgradeNeutral ➝ Outperform$30.00Low
2/17/2023HC WainwrightReiterated RatingBuy$36.00N/A
1/30/2023Canaccord Genuity GroupBoost TargetBuy$33.00 ➝ $40.00Low
1/10/2023Piper SandlerBoost TargetOverweight$38.00 ➝ $42.00Low
12/13/2022Stifel NicolausInitiated CoverageHold$22.00Low
12/5/2022Wells Fargo & CompanyInitiated CoverageOverweight$28.00Low
10/20/2022Evercore ISILower Target$30.00Low
10/20/2022SVB LeerinkLower TargetOutperform$45.00 ➝ $38.00Low
10/14/2022HC WainwrightLower TargetBuy$42.00 ➝ $36.00Low
10/13/2022Piper SandlerLower TargetOverweight$39.00 ➝ $38.00Low
9/21/2022Bryan, Garnier & CoInitiated CoverageSell$17.00Low
8/15/2022Piper SandlerLower Target$41.00 ➝ $39.00Low
8/9/2022Evercore ISILower Target$35.00Low
8/9/2022BarclaysLower Target$37.00Low
8/8/2022HC WainwrightLower TargetBuy$46.00 ➝ $42.00Low
8/5/2022SVB LeerinkBoost TargetOutperform$42.00 ➝ $45.00Low
7/26/2022Piper SandlerBoost TargetOverweight$40.00 ➝ $41.00Low
7/14/2022Canaccord Genuity GroupReiterated RatingBuy$42.00Low
5/17/2022HC WainwrightBoost TargetBuy$45.00 ➝ $46.00N/A
5/6/2022Piper SandlerLower Target$42.00 ➝ $40.00High
3/30/2022Piper SandlerInitiated CoverageOverweight$42.00Medium
2/28/2022HC WainwrightInitiated CoverageBuy$45.00Medium
12/16/2021BarclaysBoost TargetOverweight$36.00 ➝ $40.00Medium
12/16/2021SVB LeerinkBoost TargetOutperform$37.00 ➝ $42.00Medium
8/17/2021SVB LeerinkBoost TargetOutperform$27.00 ➝ $37.00High
6/6/2021SVB LeerinkReiterated RatingBuyLow
5/26/2021SVB LeerinkBoost TargetOutperform$27.00 ➝ $35.00High
5/26/2021Evercore ISILower TargetOutperform$30.00 ➝ $23.00High
5/26/2021WedbushDowngradeOutperform ➝ Neutral$19.00High
5/26/2021BarclaysLower TargetOverweight$40.00 ➝ $34.00High
5/7/2021BMO Capital MarketsLower TargetOutperform$43.00 ➝ $38.00High
4/12/2021WedbushLower TargetOutperform$46.00 ➝ $39.00High
3/3/2021SVB LeerinkReiterated RatingOutperformHigh
3/2/2021BMO Capital MarketsLower Target$48.00 ➝ $43.00High
2/3/2021BMO Capital MarketsBoost TargetPositive ➝ Outperform$33.00 ➝ $48.00High
11/23/2020Evercore ISIInitiated CoverageOutperformMedium
(Data available from 4/1/2018 forward)

News Sentiment Rating

0.98 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/3/2022
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/3/2022
  • 5 very positive mentions
  • 14 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
11/2/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/2/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/1/2023
  • 4 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/31/2023
  • 11 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/2/2023
  • 7 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/1/2023

Current Sentiment

  • 7 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Travere Therapeutics logo
Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.
Read More

Today's Range

Now: $22.49
Low: $22.04
High: $22.75

50 Day Range

MA: $21.34
Low: $17.82
High: $22.89

52 Week Range

Now: $22.49
Low: $17.82
High: $30.35

Volume

1,106,533 shs

Average Volume

1,227,834 shs

Market Capitalization

$1.46 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.48

Frequently Asked Questions

What sell-side analysts currently cover shares of Travere Therapeutics?

The following Wall Street analysts have issued reports on Travere Therapeutics in the last year: Barclays PLC, Bryan, Garnier & Co, Canaccord Genuity Group Inc., Evercore ISI, Guggenheim, HC Wainwright, Piper Sandler, Stifel Nicolaus, SVB Leerink LLC, Wedbush, and Wells Fargo & Company.
View the latest analyst ratings for TVTX.

What is the current price target for Travere Therapeutics?

11 Wall Street analysts have set twelve-month price targets for Travere Therapeutics in the last year. Their average twelve-month price target is $32.91, suggesting a possible upside of 46.3%. Canaccord Genuity Group Inc. has the highest price target set, predicting TVTX will reach $42.00 in the next twelve months. Bryan, Garnier & Co has the lowest price target set, forecasting a price of $17.00 for Travere Therapeutics in the next year.
View the latest price targets for TVTX.

What is the current consensus analyst rating for Travere Therapeutics?

Travere Therapeutics currently has 1 sell rating, 1 hold rating and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TVTX will outperform the market and that investors should add to their positions of Travere Therapeutics.
View the latest ratings for TVTX.

What other companies compete with Travere Therapeutics?

Other companies that are similar to Travere Therapeutics include DICE Therapeutics, Avidity Biosciences, Syndax Pharmaceuticals, Rocket Pharmaceuticals and Morphic. Learn More about companies similar to Travere Therapeutics.

How do I contact Travere Therapeutics' investor relations team?

Travere Therapeutics' physical mailing address is 3721 VALLEY CENTRE DR. SUITE 200, SAN DIEGO CA, 92130. The company's listed phone number is (888) 969-7879 and its investor relations email address is [email protected] The official website for Travere Therapeutics is www.retrophin.com. Learn More about contacing Travere Therapeutics investor relations.